Full history for every metric is available with a Kvantra account
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
Key financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 6,224 | 2,348 | 914 | 3,745 | 6,295 | 3,724 | 3,724 |
| Operating profit | CNY m | 674 | 674 | |||||
| Net profit | CNY m | 1,919 | 839 | -588 | 77 | 1,993 | 483 | 483 |
| EPS reported | CNY | 0.55 | 0.55 | |||||
| Operating cashflow per share | CNY | 0.10 | 0.10 | |||||
| Capex per share | CNY | 1.34 | 1.34 | |||||
| FCF per share | CNY | -1.24 | -1.24 | |||||
| Free cash flow | CNY m | -1,093 | -937 | |||||
| Net debt | CNY m | 513 | 513 | |||||
| Book value equity | CNY m | 8,508 | 8,508 | |||||
| Book value per share | CNY | 9.67 | 9.67 | |||||
| Number of shares | m | 879.97 | 879.97 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 16.37 | - | |||||
| P/B LTM | x | 0.93 | 1.40 | |||||
| P/S LTM | x | 2.13 | 3.21 | |||||
| P/FCF LTM | x | -7.25 | -12.74 | |||||
| EV/EBITDA LTM | x | 8.32 | 1.38 | |||||
| EV/Sales LTM | x | 2.35 | 3.34 | |||||
| Earnings Yield LTM | % | 6.11% | 4.04% | |||||
| FCF Yield | % | -13.80% | -7.85% | |||||
| Quality | ||||||||
| ROE | % | 5.67% | 5.87% | |||||
| ROIC | % | 5.16% | 5.16% | |||||
| Operating margin | % | 18.11% | 18.11% | |||||
| Gross margin | % | 75.03% | 75.03% | |||||
| FCF/Sales | % | -29.34% | -29.34% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -75.66% | -75.66% | |||||
| Sales Growth YoY | % | -40.84% | -40.84% | |||||
| Net Income Growth YoY | % | -75.78% | -75.78% | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | -71.35% | -71.35% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.49 | -0.42 | |||||
| Net Debt/EBITDA | x | 0.79 | 0.79 | |||||
| EBIT/Net interest | x | 24.75 | 24.75 | |||||
| Net debt/market cap | % | 6.48% | 4.30% | |||||
| Net debt/Equity | x | 0.06 | 0.06 | |||||
| Gross debt/equity | x | 0.26 | 0.26 | |||||
Company overview
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is primarily involved in the development, production, and sale of pharmaceutical goods across the People's Republic of China. Its product range targets key therapeutic areas such as antiviral treatments, endocrine and metabolic conditions, and cardiovascular ailments. In addition to finished pharmaceuticals, the company also manufactures active pharmaceutical ingredients, conducts research and development for medical devices, new drugs, and biotechnology, and provides medical consulting services. Their products reach hospitals and various medical institutions via a comprehensive network of distributors. The company has established important strategic collaborations, notably a framework agreement with Alibaba Health Technology (China) Limited for influenza-related projects, and partnerships with Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd., and China National Accord Medicines Corporation Ltd. Founded in 2001 and based in Yichang, China, the company adopted its current name in May 2015, having previously been known as Yichang Changjiang Pharmaceutical Company Limited. It operates as a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is primarily involved in the development, production, and sale of pharmaceutical goods across the People's Republic of China. Its product range targets key therapeutic areas such as antiviral treatments, endocrine and metabolic conditions, and cardiovascular ailments. In addition to finished pharmaceuticals, the company also manufactures active pharmaceutical ingredients, conducts research and development for medical devices, new drugs, and biotechnology, and provides medical consulting services. Their products reach hospitals and various medical institutions via a comprehensive network of distributors. The company has established important strategic collaborations, notably a framework agreement with Alibaba Health Technology (China) Limited for influenza-related projects, and partnerships with Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd., and China National Accord Medicines Corporation Ltd. Founded in 2001 and based in Yichang, China, the company adopted its current name in May 2015, having previously been known as Yichang Changjiang Pharmaceutical Company Limited. It operates as a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free